225Ac-PSMA-617 for Therapy of Prostate Cancer
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Prostate-specific membrane antigen (PSMA)-targeting radio-ligand therapy with beta-emitting 177Lutetium has already been investigated in several early phase dosimetry studies, demonstrated promising results in phase-2, and recently the first phase-3 trial finished recruitment. In contrast, PSMA-targeting alpha-particle therapy (TAT) has only been evaluated in few preclinical experiments, preliminary dosimetry attempts and some retrospective observational studies, yet. First clinical experience with 225Ac-PSMA-617 demonstrates promising antitumor activity with a 63%-70% PSA>50%-response rate, 10-15 months duration of response and complete remissions in approximately ten percent of patients, some of them with enduring relapse-free survival. Nevertheless, without comparative trials there is no prove whether, applied in identical clinical situations, 225Ac-PSMA-617 is really more efficiently than 177Lu-PSMA-617 or vice versa. However, there is some good rationale, that PSMA-TAT might have advantages in particular clinical indications. This includes patients with diffuse type red-marrow infiltration by reducing off-target radiation to surrounding cells; ablation of micrometastases after favorable response to other previous therapy or someday in early stage disease. Also treatment escalation of patients, either with poor response to 177Lu-PSMA or harboring adverse prognostic biomarkers, appears promising. In preclinical research, alpha-radiation demonstrated stronger induction of abscopal effects than beta-radiation; favoring its usage as a combination partner with immunotherapies. So, further evaluation of PSMA-TAT is definitely warranted. Recently, de-escalated treatment protocols and application of 225Ac/177Lu-PSMA "cocktail"-regimens improved the tolerability of 225Ac-PSMA-617 TAT, reducing the risk for development dry-mouth syndrome. This opens new avenues for future application in earlier stage disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505
Self-citationEfforts to Control the Errant Products of a Targeted In vivo Generator
Singh Jaggi, J., Kappel, B. J., McDevitt, M. R., Sgouros, G., Flombaum, C. D., Cabassa, C., & Scheinberg, D. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3096 · Cited by 98
Cited by
Radiotheranostics in oncology: current challenges and emerging opportunities
Bodei, L., Herrmann, K., Schöder, H., Scott, A. M., & Lewis, J. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00652-y · Cited by 414
Radiolabelling of nanomaterials for medical imaging and therapy
Pellico, J., Gawne, P. J., & T. M. de Rosales, R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00384k · Cited by 304
Feuerecker, B., Tauber, R., Knorr, K., Heck, M., Beheshti, A., Seidl, C., Bruchertseifer, F., Pickhard, A., Gafita, A., Kratochwil, C., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.11.013 · Cited by 277
Self-citationTargeted alpha therapy: progress in radionuclide production, radiochemistry, and applications.
Nelson, B. J. B., Andersson, J. D., & Wuest, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010049 · Cited by 194
Combination Strategies to Improve Targeted Radionuclide Therapy
Chan, T. G., O’Neill, E., Habjan, C., & Cornelissen, B. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.248062 · Cited by 91
“In addition, although this review focused on beta-emitting TRTs, there is growing interest in the use of alpha and Auger emitters ( 91 – 93 ).”
Background
Metadata
- Authors
- Kratochwil, C., Haberkorn, U., & Giesel, F. L.
- Venue
- Seminars in Nuclear Medicine
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 50
- Issue
- 2
- Pages
- 133-140
- ISSN
- 0001-2998 (ISSN-L)
- OpenAlex
- W3005893761
- Cited by
- 136
- References
- 2
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 225Ac-PSMA-617 for Therapy of Prostate Cancer. https://app.cochat.ai/papers/10.1053/j.semnuclmed.2020.02.004
- The paper
- Kratochwil, C., Haberkorn, U., & Giesel, F. L. (2020). 225Ac-PSMA-617 for Therapy of Prostate Cancer. Seminars in Nuclear Medicine. https://doi.org/10.1053/j.semnuclmed.2020.02.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.